FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2066960839> ?p ?o ?g. }

• W2066960839 endingPage "436" @default.
• W2066960839 startingPage "422" @default.
• W2066960839 abstract "While glyco-engineered monoclonal antibodies (mAbs) with improved antibody-dependent cell-mediated cytotoxicity (ADCC) are reaching the market, extensive efforts have also been made to improve their pharmacokinetic properties to generate biologically superior molecules. Most therapeutic mAbs are human or humanized IgG molecules whose half-life is dependent on the neonatal Fc receptor FcRn. FcRn reduces IgG catabolism by binding to the Fc domain of endocytosed IgG in acidic lysosomal compartments, allowing them to be recycled into the blood. Fc-engineered mAbs with increased FcRn affinity resulted in longer in vivo half-life in animal models, but also in healthy humans. These Fc-engineered mAbs were obtained by alanine scanning, directed mutagenesis or in silico approach of the FcRn binding site. In our approach, we applied a random mutagenesis technology (MutaGenTM) to generate mutations evenly distributed over the whole Fc sequence of human IgG1. IgG variants with improved FcRn-binding were then isolated from these Fc-libraries using a pH-dependent phage display selection process. Two successive rounds of mutagenesis and selection were performed to identify several mutations that dramatically improve FcRn binding. Notably, many of these mutations were unpredictable by rational design as they were located distantly from the FcRn binding site, validating our random molecular approach. When produced on the EMABling® platform allowing effector function increase, our IgG variants retained both higher ADCC and higher FcRn binding. Moreover, these IgG variants exhibited longer half-life in human FcRn transgenic mice. These results clearly demonstrate that glyco-engineering to improve cytotoxicity and protein-engineering to increase half-life can be combined to further optimize therapeutic mAbs." @default.
• W2066960839 created "2016-06-24" @default.
• W2066960839 creator A5007872375 @default.
• W2066960839 creator A5012404119 @default.
• W2066960839 creator A5016151077 @default.
• W2066960839 creator A5032013199 @default.
• W2066960839 creator A5038686780 @default.
• W2066960839 creator A5047345459 @default.
• W2066960839 creator A5058089709 @default.
• W2066960839 creator A5066731794 @default.
• W2066960839 creator A5070124338 @default.
• W2066960839 creator A5072975390 @default.
• W2066960839 creator A5085667679 @default.
• W2066960839 creator A5086318639 @default.
• W2066960839 creator A5089114288 @default.
• W2066960839 date "2014-01-15" @default.
• W2066960839 modified "2023-10-16" @default.
• W2066960839 title "Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody" @default.
• W2066960839 cites W129321786 @default.
• W2066960839 cites W1529809181 @default.
• W2066960839 cites W1547437295 @default.
• W2066960839 cites W1914229355 @default.
• W2066960839 cites W1944996883 @default.
• W2066960839 cites W1963563607 @default.
• W2066960839 cites W1965205681 @default.
• W2066960839 cites W1966258128 @default.
• W2066960839 cites W1967710039 @default.
• W2066960839 cites W1971242419 @default.
• W2066960839 cites W1972018125 @default.
• W2066960839 cites W1972687417 @default.
• W2066960839 cites W1973356354 @default.
• W2066960839 cites W1979162895 @default.
• W2066960839 cites W1982183807 @default.
• W2066960839 cites W1983274526 @default.
• W2066960839 cites W1983565271 @default.
• W2066960839 cites W1984233517 @default.
• W2066960839 cites W1984335567 @default.
• W2066960839 cites W1988795495 @default.
• W2066960839 cites W1993544501 @default.
• W2066960839 cites W1995044130 @default.
• W2066960839 cites W1995923662 @default.
• W2066960839 cites W1996045402 @default.
• W2066960839 cites W1997401427 @default.
• W2066960839 cites W2002190580 @default.
• W2066960839 cites W2003710369 @default.
• W2066960839 cites W2009900556 @default.
• W2066960839 cites W2024972268 @default.
• W2066960839 cites W2025605905 @default.
• W2066960839 cites W2028715633 @default.
• W2066960839 cites W2035464330 @default.
• W2066960839 cites W2036601374 @default.
• W2066960839 cites W2041126185 @default.
• W2066960839 cites W2044360617 @default.
• W2066960839 cites W2048504768 @default.
• W2066960839 cites W2061641422 @default.
• W2066960839 cites W2065900855 @default.
• W2066960839 cites W2070360032 @default.
• W2066960839 cites W2071843728 @default.
• W2066960839 cites W2072958011 @default.
• W2066960839 cites W2074900601 @default.
• W2066960839 cites W2078111332 @default.
• W2066960839 cites W2089036873 @default.
• W2066960839 cites W2091229935 @default.
• W2066960839 cites W2091887204 @default.
• W2066960839 cites W2093117233 @default.
• W2066960839 cites W2093394631 @default.
• W2066960839 cites W2101193123 @default.
• W2066960839 cites W2102946412 @default.
• W2066960839 cites W2104198642 @default.
• W2066960839 cites W2104446771 @default.
• W2066960839 cites W2119562248 @default.
• W2066960839 cites W2121285724 @default.
• W2066960839 cites W2122080125 @default.
• W2066960839 cites W2122618533 @default.
• W2066960839 cites W2127214162 @default.
• W2066960839 cites W2130611069 @default.
• W2066960839 cites W2137354517 @default.
• W2066960839 cites W2138906847 @default.
• W2066960839 cites W2143562636 @default.
• W2066960839 cites W2148090354 @default.
• W2066960839 cites W2149725620 @default.
• W2066960839 cites W2162074340 @default.
• W2066960839 cites W2162907283 @default.
• W2066960839 cites W25755508 @default.
• W2066960839 cites W4233909860 @default.
• W2066960839 doi "https://doi.org/10.4161/mabs.27854" @default.
• W2066960839 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3984331" @default.
• W2066960839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24492301" @default.
• W2066960839 hasPublicationYear "2014" @default.
• W2066960839 type Work @default.
• W2066960839 sameAs 2066960839 @default.
• W2066960839 citedByCount "41" @default.
• W2066960839 countsByYear W20669608392014 @default.
• W2066960839 countsByYear W20669608392015 @default.
• W2066960839 countsByYear W20669608392016 @default.
• W2066960839 countsByYear W20669608392017 @default.
• W2066960839 countsByYear W20669608392018 @default.
• W2066960839 countsByYear W20669608392019 @default.

• next